This is the authors' abstract. We don't add key points for this paper.
In their interesting paper, Arrigo et al. (1) investigated longitudinally body mass index (BMI) evolution and prevalence of obesity in girls with idiopathic central precocious puberty (CPP) who were treated with luteinizing hormone-releasing hormone (LHRH) analogs (LHRHa) for at least 2 years. They demonstrated that suppression of the pituitary–gonadal axis function was accompanied by a significant decrease in being overweight. They observed that girls with CPP are frequently obese at diagnosis, suggesting that the pretreatment increase in BMI is due to pubertal hormonal changes and secondary changes in body fat, rather than being a result of CPP (1). We have retrospectively reviewed 29 female patients with idiopathic CPP. The main criteria for diagnosis of idiopathic CPP were (1) onset of breast development and/or menses before 8 years of age, (2) pubertal luteinizing hormone (LH) response to exogenous LHRH (LH peak > 10 IU/l), (3) no evidence of hypothalamo–pituitary lesions at magnetic resonance imaging and (4) no additional conditions that might affect BMI. Predicted height was calculated using a computerized Byley–Pinneau method (2). We assessed height SDS, BMI and BMI SDS (3) before, 1 year after the beginning of therapy, at the end of therapy and 2.5 years after the end of therapy. A group of 45 healthy girls with normal onset of puberty was matched for age or for pubertal stage. Statistical analysis was performed with χ2 test and paired sample t-test (P was considered significant if < 0.01).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Traggiai et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: